Mischke R, Waterston M, Eckersall P D
Small Animal Clinic, Hannover School of Veterinary Medicine, Hannover, Germany.
Vet J. 2007 Jul;174(1):188-92. doi: 10.1016/j.tvjl.2006.05.018. Epub 2006 Aug 9.
Acute phase proteins (APP) are regarded as a useful diagnostic tool in humans with lymphomas, leukaemias and multiple myeloma. C-reactive protein (CRP) and haptoglobin concentrations were measured in dogs with malignant multicentric (high grade) lymphoma (n=16), acute lymphoblastic leukaemia (ALL) (n=11), chronic lymphocytic leukaemia (CLL) (n=7) and multiple myeloma (n=8). Twenty-five healthy dogs served as controls. Measurements of the CRP plasma concentration were performed using a commercial ELISA and haptoglobin was measured with an assay based on its haemoglobin binding capacity. Global group comparisons using Kruskal-Wallis-test revealed significant group differences for both APPs (P<0.0001). Median CRP concentrations were increased in all groups with neoplastic lymphatic disorders (lymphoma: 37.2mg/L, ALL: 47.8mg/L, CLL: 35.5mg/L, myeloma: 17.6mg/L) compared to controls (1.67mg/L; P<0.001). Compared to the healthy controls (median=0.59g/L), haptoglobin was especially increased in dogs with ALL (6.8g/L, P<0.0001) followed by dogs with malignant lymphoma (3.8g/L, P<0.0001), CLL (3.2g/L, P=0.0008), and multiple myeloma (3.0g/L, P=0.0163). For both APPs, a wide range of values was found in all patient groups. The results indicate that particularly severe and acute lymphatic neoplasia, such as high grade lymphoma and ALL, cause significant acute phase reactions in dogs and must be included in the differential diagnoses of increased blood levels of these APPs.
急性期蛋白(APP)被视为人类淋巴瘤、白血病和多发性骨髓瘤的一种有用诊断工具。对患有恶性多中心(高级别)淋巴瘤(n = 16)、急性淋巴细胞白血病(ALL)(n = 11)、慢性淋巴细胞白血病(CLL)(n = 7)和多发性骨髓瘤(n = 8)的犬只测量了C反应蛋白(CRP)和触珠蛋白浓度。25只健康犬作为对照。使用商业ELISA法检测CRP血浆浓度,基于触珠蛋白与血红蛋白结合能力的检测方法测量触珠蛋白。使用Kruskal-Wallis检验进行总体组间比较,结果显示两种APP在组间均存在显著差异(P < 0.0001)。与对照组(1.67mg/L;P < 0.001)相比,所有患有肿瘤性淋巴疾病的组中CRP中位数浓度均升高(淋巴瘤:37.2mg/L,ALL:47.8mg/L,CLL:35.5mg/L,骨髓瘤:17.6mg/L)。与健康对照组(中位数 = 0.59g/L)相比,触珠蛋白在ALL犬中尤其升高(6.8g/L,P < 0.0001),其次是恶性淋巴瘤犬(3.8g/L,P < 0.0001)、CLL犬(3.2g/L,P = 0.0008)和多发性骨髓瘤犬(3.0g/L,P = 0.0163)。在所有患者组中,两种APP均发现有广泛的数值范围。结果表明,特别是严重的急性淋巴肿瘤,如高级别淋巴瘤和ALL,会在犬只中引起显著的急性期反应,在这些APP血液水平升高的鉴别诊断中必须考虑到。